This page shows the latest Nektar Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Merck (MSD) has signed a deal to acquire Pandion Therapeutics for approximately $1.85bn, gaining access to a pipeline of immune modulators for the treatment of autoimmune diseases. ... A number of other pharma companies are also developing IL-2 therapies,
Verdict closely follows rejection of Nektar’s opioid analgesic. The FDA’s Anesthetic and Analgesic Committee has rejected yet another opioid drug – this time Intellipharmaceutics’ extended-release oxycodone tablet Aximiris. ... Proving the
Panelists unanimously rejected use of the chronic back pain drug. Nektar Therapeutics has been hit with a unanimous FDA panel rejection of its opioid painkiller, over concerns of drug abuse and ... Although the rejection is a blow to Nektar, the opioid
Adds research programmes in an additional two cancer types. Bristol-Myers Squibb has expanded its development programme with Nektar, sending shares in the biotech soaring by nearly 20%. ... In addition to the Nektar collaboration and research, BMS has
Treg therapy developed by Nektar Therapeutics. ... Similarly, Lilly/Nektar’s NKTR-358 also targets the IL-2 receptor complex to stimulate Treg production.
Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference. ... Nektar Therapeutics has said the company’s $3.6bn deal with Bristol-Myers Squibb for immuno-oncology drug NKTR-214 won’t be affected by the big pharma’s
More from news
Approximately 3 fully matching, plus 18 partially matching documents found.
article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Nektar Therapeutics’ CD122 agonist NKTR-214 posted mixed results in mid-stage trials alongside Opdivo in solid
A clinical co-operation between Bristol-Myers Squibb and Nektar Therapeutics was closed under which Opdivo [nivolumab] will be evaluated in combination with Nektar's NKTR-214 in phase I/II ... 639. Cynapsus Therapeutics / Sunovion. Acquisition corporate.
licence. 230. Moderna Therapeutics/ Merck &Co. mRNA-based personalised cancer vaccines; exclusive for Keytruda combinations (discovery). ... acquisition company. 105. Nektar Therapeutics/ Daiichi Sankyo Europe. Onzeald (etirinotecan pegol), long-acting
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
He has also held roles for Nektar Therapeutics, Bayer and Pfizer.
He joins as an independent director. California, US-based Nektar Therapeutics has appointed Jeff Ajer as its independent director to the company’s board of directors, following his 25 years’ of ... Howard Robin, president and CEO, Nektar Therapeutics,
Comes amidst MSD’s recent takeover of the antibiotic specialist. InVivo Therapeutics has appointed former Cubist executive team leader Dr Lorianne Masuoka as its new chief medical officer. ... Prior to her time at Cubist, she served in various roles of
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...